# Ruxolitinib in Seborrheic Dermatitis

> **NCT05787860** · PHASE2 · COMPLETED · sponsor: **Icahn School of Medicine at Mount Sinai** · enrollment: 45 (actual)

## Conditions studied

- Seborrheic Dermatitis

## Interventions

- **DRUG:** Ruxolitinib 1.5% Cream

## Key facts

- **NCT ID:** NCT05787860
- **Lead sponsor:** Icahn School of Medicine at Mount Sinai
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-15
- **Primary completion:** 2024-01-26
- **Final completion:** 2024-01-26
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2025-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05787860

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05787860, "Ruxolitinib in Seborrheic Dermatitis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05787860. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*